Search

Displaying results 3811 - 3820 of 4238 in total
  1. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.

  2. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.

  3. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...

  4. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  5. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and ...

  6. Drug

    Valinomycin

    go.drugbank.com/drugs/DB14057
    Experimental

    (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

  7. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  8. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

  9. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  10. Drug

    3'-phospho-5'-adenylyl sulfate

    go.drugbank.com/drugs/DB02902
    Experimental

    3'-phospho-5'-adenylyl sulfate is a key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate